Inflammatory skin allergies, including atopic dermatitis, allergic contact dermatitis, and urticaria, represent a significant global health burden affecting millions of individuals worldwide. The Janus kinase 3 (JAK3), a critical member of the JAK-STAT signaling pathway, has emerged as a promising therapeutic target due to its selective expression in immune cells and its pivotal role in mediating cytokine-driven inflammation. While synthetic JAK inhibitors have demonstrated clinical efficacy, their systemic immunosuppressive effects, hepatotoxicity, and high costs limit their widespread application. This study presents a comprehensive in silico approach to identify, characterize, and evaluate natural product-based JAK3 inhibitors as safer alternatives for topical management of skin allergies. Using the Protein Data Bank (PDB ID: 7C3N) as the target receptor, we performed database screening via IMPPAT and Dr. Duke's Phytochemical and Ethnobotanical Databases to identify medicinal plants with established anti-allergic and anti-inflammatory properties. From an initial pool of over 1,500 plants, seven medicinally important species—Aloe vera, Ocimum sanctum, Cucumis sativus, Azadirachta indica, Withania somnifera, Cocos nucifera, and Lawsonia inermis—were selected based on local availability and accessibility. Phytochemical profiling yielded 92 phytoconstituents, which were subjected to molecular docking analysis using Schrodinger Maestro 12.5 against the delgocitinib binding site of JAK3. The docking results revealed cucurbitacin-C (docking score: -12.406), quercetin (-9.98), luteolin (-9.243), and chrysophanic acid (-9.015) as top-scoring candidates with binding affinities comparable to the standard drug delgocitinib (-12.406). ADMET and physicochemical profiling via pKCSM and SwissADME demonstrated that all lead compounds adhered to Lipinski's Rule of Five and Veber's rules, indicating favorable drug-likeness, oral bioavailability, and safety profiles. The identified